AU2016369612B2 - Polynucleotides encoding methylmalonyl-CoA mutase - Google Patents
Polynucleotides encoding methylmalonyl-CoA mutase Download PDFInfo
- Publication number
- AU2016369612B2 AU2016369612B2 AU2016369612A AU2016369612A AU2016369612B2 AU 2016369612 B2 AU2016369612 B2 AU 2016369612B2 AU 2016369612 A AU2016369612 A AU 2016369612A AU 2016369612 A AU2016369612 A AU 2016369612A AU 2016369612 B2 AU2016369612 B2 AU 2016369612B2
- Authority
- AU
- Australia
- Prior art keywords
- utp
- polynucleotide
- methyl
- ctp
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
- C12Y504/99002—Methylmalonyl-CoA mutase (5.4.99.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269089P | 2015-12-17 | 2015-12-17 | |
| US201562269092P | 2015-12-17 | 2015-12-17 | |
| US62/269,089 | 2015-12-17 | ||
| US62/269,092 | 2015-12-17 | ||
| US201562273112P | 2015-12-30 | 2015-12-30 | |
| US201562273108P | 2015-12-30 | 2015-12-30 | |
| US62/273,112 | 2015-12-30 | ||
| US62/273,108 | 2015-12-30 | ||
| US201662274722P | 2016-01-04 | 2016-01-04 | |
| US201662274733P | 2016-01-04 | 2016-01-04 | |
| US201662274726P | 2016-01-04 | 2016-01-04 | |
| US201662274727P | 2016-01-04 | 2016-01-04 | |
| US62/274,727 | 2016-01-04 | ||
| US62/274,722 | 2016-01-04 | ||
| US62/274,733 | 2016-01-04 | ||
| US62/274,726 | 2016-01-04 | ||
| US201662338456P | 2016-05-18 | 2016-05-18 | |
| US201662338478P | 2016-05-18 | 2016-05-18 | |
| US62/338,478 | 2016-05-18 | ||
| US62/338,456 | 2016-05-18 | ||
| US201662409343P | 2016-10-17 | 2016-10-17 | |
| US62/409,343 | 2016-10-17 | ||
| PCT/US2016/067393 WO2017106799A1 (en) | 2015-12-17 | 2016-12-16 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016369612A1 AU2016369612A1 (en) | 2018-06-14 |
| AU2016369612B2 true AU2016369612B2 (en) | 2023-06-01 |
Family
ID=57738001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016369612A Ceased AU2016369612B2 (en) | 2015-12-17 | 2016-12-16 | Polynucleotides encoding methylmalonyl-CoA mutase |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10426738B2 (https=) |
| EP (1) | EP3390630B1 (https=) |
| JP (1) | JP7065036B2 (https=) |
| AU (1) | AU2016369612B2 (https=) |
| CA (1) | CA3007108A1 (https=) |
| IL (2) | IL259667B (https=) |
| MA (1) | MA43568A (https=) |
| WO (1) | WO2017106799A1 (https=) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| MA43568A (fr) | 2015-12-17 | 2018-11-14 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| WO2017201347A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2017201348A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| EP3458106A4 (en) | 2016-05-18 | 2020-03-18 | Modernatx, Inc. | POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA |
| US20190298657A1 (en) * | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| MA45032A (fr) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US20200131498A1 (en) * | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019051092A2 (en) * | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | BIOMARKERS OF ORGANIC ACIDEMICS |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| CN111712468A (zh) | 2017-12-22 | 2020-09-25 | 北卡罗莱纳州立大学 | 聚合物荧光团、包含其的组合物及制备和使用其的方法 |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| JP2021512090A (ja) * | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| CN108704162A (zh) * | 2018-08-08 | 2018-10-26 | 中国科学院长春应用化学研究所 | 一种吸水敷料及其制备方法 |
| EP3849617A1 (en) * | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| US20220162278A1 (en) * | 2019-02-27 | 2022-05-26 | The Regents Of The University Of Michigan | Carbamoyl phosphate synthatase-1 for the treatment and prevention of liver injury |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| JP7681617B2 (ja) | 2020-04-09 | 2025-05-22 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質ナノ粒子組成物 |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| WO2022204369A1 (en) * | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US20240269248A1 (en) * | 2021-05-19 | 2024-08-15 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| US20250195666A1 (en) * | 2021-05-20 | 2025-06-19 | City Of Hope | Mir-142 compounds and uses thereof |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| AU2024347117A1 (en) * | 2023-09-21 | 2026-04-09 | The Board Of Regents Of The University Of Texas System | Endogenous mitochondria targeting signal peptides and uses thereof |
| WO2025126242A1 (en) * | 2023-12-11 | 2025-06-19 | Dr. Reddy's Institute Of Life Sciences | Nucleic acid sequence(s) and construct(s) for treating methylmalonic acidemia and method(s) thereof |
| CN118360253A (zh) * | 2024-05-11 | 2024-07-19 | 中山大学附属第六医院 | 一种干扰甲基丙二酰辅酶a变位酶表达的细胞系及其构建方法与应用 |
| WO2026014954A1 (ko) * | 2024-07-10 | 2026-01-15 | 주식회사 엣진 | 개선된 염기 교정 효율을 갖는 미토콘드리아 dna 염기 에디터 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013151666A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| WO2014143884A2 (en) * | 2013-03-15 | 2014-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic methylmalonyl-coa mutase transgene for the treatment of mut class methylmalonic acidemia (mma) |
| WO2015017519A1 (en) * | 2013-07-30 | 2015-02-05 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
| WO2016172574A2 (en) * | 2015-04-24 | 2016-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tagged form of mut enzyme, genetic constructs incorporating it, and its use in gene therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| EP0755268A1 (en) | 1994-04-11 | 1997-01-29 | Baylor College Of Medicine | Compositions and methods for gene therapy to treat disease |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20070122885A1 (en) | 2005-08-22 | 2007-05-31 | Fermalogic, Inc. | Methods of increasing production of secondary metabolites by manipulating metabolic pathways that include methylmalonyl-coa |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| CA2816925C (en) * | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| SE535869C2 (sv) * | 2010-04-01 | 2013-01-22 | Elways Ab | Ett för ett eller flera, elektriskt framdrivbara, fordon anpassat system (Laddningssystem). |
| CA2863964C (en) | 2012-02-07 | 2021-10-26 | Global Bio Therapeutics Usa, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014089212A1 (en) | 2012-12-05 | 2014-06-12 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of metabolic disorders |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014151927A1 (en) * | 2013-03-14 | 2014-09-25 | Ipg Photonics Corporation | Universal fiber optic connector |
| SG11201507474QA (en) | 2013-03-14 | 2015-10-29 | Shire Human Genetic Therapies | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS |
| US9944918B2 (en) | 2013-03-15 | 2018-04-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA) |
| SMT202200502T1 (it) * | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11389546B2 (en) | 2015-12-09 | 2022-07-19 | Modernatx, Inc. | Heterologous UTR sequences for enhanced mRNA expression |
| MA43568A (fr) | 2015-12-17 | 2018-11-14 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| WO2017147720A1 (en) | 2016-03-04 | 2017-09-08 | Exerkine Corporation | Method for treating a central nervous system disorder |
| US11377656B2 (en) | 2016-03-10 | 2022-07-05 | Novartis Ag | Chemically modified messenger RNA's |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| EP3458106A4 (en) | 2016-05-18 | 2020-03-18 | Modernatx, Inc. | POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA |
| MA45032A (fr) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë |
| WO2017201347A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2017201348A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| US20200368162A1 (en) | 2017-02-24 | 2020-11-26 | Modernatx, Inc. | Nucleic Acid-Based Therapy of Muscular Dystrophies |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| EP3849617A1 (en) | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
-
2016
- 2016-12-16 MA MA043568A patent/MA43568A/fr unknown
- 2016-12-16 JP JP2018551890A patent/JP7065036B2/ja active Active
- 2016-12-16 AU AU2016369612A patent/AU2016369612B2/en not_active Ceased
- 2016-12-16 CA CA3007108A patent/CA3007108A1/en active Pending
- 2016-12-16 WO PCT/US2016/067393 patent/WO2017106799A1/en not_active Ceased
- 2016-12-16 EP EP16822592.8A patent/EP3390630B1/en active Active
-
2018
- 2018-05-29 IL IL259667A patent/IL259667B/en unknown
- 2018-06-07 US US16/002,472 patent/US10426738B2/en active Active
- 2018-06-07 US US16/002,376 patent/US10406112B2/en active Active
- 2018-08-27 US US16/113,814 patent/US20190022019A1/en not_active Abandoned
-
2019
- 2019-07-18 US US16/515,256 patent/US11504337B2/en active Active
-
2021
- 2021-12-19 IL IL289098A patent/IL289098A/en unknown
-
2022
- 2022-11-18 US US17/989,941 patent/US20230270685A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013151666A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| WO2014143884A2 (en) * | 2013-03-15 | 2014-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic methylmalonyl-coa mutase transgene for the treatment of mut class methylmalonic acidemia (mma) |
| WO2015017519A1 (en) * | 2013-07-30 | 2015-02-05 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
| WO2016172574A2 (en) * | 2015-04-24 | 2016-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tagged form of mut enzyme, genetic constructs incorporating it, and its use in gene therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019500430A (ja) | 2019-01-10 |
| MA43568A (fr) | 2018-11-14 |
| JP7065036B2 (ja) | 2022-05-11 |
| WO2017106799A1 (en) | 2017-06-22 |
| CA3007108A1 (en) | 2017-06-22 |
| IL259667B (en) | 2022-01-01 |
| US20230270685A1 (en) | 2023-08-31 |
| AU2016369612A1 (en) | 2018-06-14 |
| US20190022019A1 (en) | 2019-01-24 |
| US10406112B2 (en) | 2019-09-10 |
| US11504337B2 (en) | 2022-11-22 |
| IL259667A (en) | 2018-07-31 |
| US10426738B2 (en) | 2019-10-01 |
| EP3390630A1 (en) | 2018-10-24 |
| US20200078314A1 (en) | 2020-03-12 |
| IL289098A (en) | 2022-02-01 |
| US20180289838A1 (en) | 2018-10-11 |
| US20180271795A1 (en) | 2018-09-27 |
| EP3390630B1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230270685A1 (en) | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | |
| US12377136B2 (en) | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria | |
| US12239742B2 (en) | Polynucleotides encoding Citrin for the treatment of Citrullinemia type 2 | |
| US12252704B2 (en) | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 | |
| US20230323371A1 (en) | Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease | |
| AU2017266948B2 (en) | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria | |
| EP3458107B1 (en) | Polynucleotides encoding jagged1 for the treatment of alagille syndrome | |
| US20200131498A1 (en) | Polynucleotides encoding methylmalonyl-coa mutase | |
| US20190298657A1 (en) | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |